About: Maribavir

An Entity of Type: person, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). The most common side effects include taste disturbance, nausea, diarrhea, vomiting and fatigue. Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. Maribavir was approved for medical use in the United States in November 2021, and in the European Union in November 2022.

Property Value
dbo:abstract
  • Maribavir (Markenname Livtencity) ist ein antiviraler Wirkstoff, der zur Behandlung des Zytomegalievirus (CMV) nach einer Transplantation eingesetzt wird. Maribavir wurde im November 2021 in den Vereinigten Staaten für die medizinische Verwendung zugelassen. (de)
  • Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). The most common side effects include taste disturbance, nausea, diarrhea, vomiting and fatigue. Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. Maribavir was approved for medical use in the United States in November 2021, and in the European Union in November 2022. (en)
dbo:alternativeName
  • Livtencity (en)
dbo:casNumber
  • 176161-24-3
dbo:chEMBL
  • 515408
dbo:drugbank
  • DB06234
dbo:fdaUniiCode
  • PTB4X93HE1
dbo:kegg
  • D04859
dbo:pubchem
  • 471161
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 21481689 (xsd:integer)
dbo:wikiPageLength
  • 17837 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1123880289 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • J05 (en)
dbp:atcSuffix
  • AX10 (en)
dbp:c
  • 15 (xsd:integer)
dbp:casNumber
  • 176161 (xsd:integer)
dbp:chembl
  • 515408 (xsd:integer)
dbp:chemspiderid
  • 413807 (xsd:integer)
dbp:cl
  • 2 (xsd:integer)
dbp:dailymedid
  • Maribavir (en)
dbp:drugbank
  • DB06234 (en)
dbp:h
  • 19 (xsd:integer)
dbp:iupacName
  • -2 (xsd:integer)
dbp:kegg
  • D04859 (en)
dbp:legalCa
  • Rx-only (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:n
  • 3 (xsd:integer)
dbp:niaidChemdb
  • 70966 (xsd:integer)
dbp:o
  • 4 (xsd:integer)
dbp:pubchem
  • 471161 (xsd:integer)
dbp:routesOfAdministration
dbp:smiles
  • CCNc1nc2ccCl (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • KJFBVJALEQWJBS-XUXIUFHCSA-N (en)
dbp:synonyms
  • 1263 (xsd:integer)
dbp:tradename
  • Livtencity (en)
dbp:unii
  • PTB4X93HE1 (en)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 450846483 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Maribavir (Markenname Livtencity) ist ein antiviraler Wirkstoff, der zur Behandlung des Zytomegalievirus (CMV) nach einer Transplantation eingesetzt wird. Maribavir wurde im November 2021 in den Vereinigten Staaten für die medizinische Verwendung zugelassen. (de)
  • Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). The most common side effects include taste disturbance, nausea, diarrhea, vomiting and fatigue. Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication. Maribavir was approved for medical use in the United States in November 2021, and in the European Union in November 2022. (en)
rdfs:label
  • Maribavir (de)
  • Maribavir (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License